Trial
NCT01185509
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech, Inc.
Condition
Breast Cancer
Intervention
trastuzumab
Why stopped
Not enough confirmed responses to continue treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-23